688712.SH
北芯生命
SSE · Healthcare · Medical - Specialties · CN
CNY 32.18
−3.13%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 599.9M | 542.1M | 316.6M | 184.0M | 92.5M |
| Cost of Revenue | 173.6M | 163.2M | 116.2M | 64.4M | 33.7M |
| Gross Profit | 426.3M | 378.9M | 200.4M | 119.6M | 58.7M |
| Operating Expenses | |||||
| R&D Expense | 91.9M | 88.5M | 101.4M | 131.4M | 132.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 79.6M | 73.9M | 69.7M | 87.8M | 205.9M |
| Selling & Marketing Expense | 142.0M | 137.1M | 109.6M | 103.0M | 75.9M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 322.7M | 306.3M | 285.1M | 322.6M | 400.2M |
| Cost and Expenses | 496.2M | 469.5M | 401.2M | 386.9M | 433.9M |
| Operating Income (EBIT) | 118.2M | 89.1M | (60.8M) | (175.0M) | (335.6M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 117.9M | 88.8M | (60.9M) | (175.1M) | (335.9M) |
| Income Tax Expense | 20.6M | 16.7M | (7.2M) | (19.9M) | (35.5M) |
| Bottom Line | |||||
| Net Income | 105.1M | 80.0M | (43.6M) | (139.8M) | (290.0M) |
| Earnings from Cont. Ops | 97.3M | 72.2M | (53.7M) | (155.2M) | (300.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 105.1M | 80.0M | (43.6M) | (139.8M) | (290.0M) |
| Per Share | |||||
| Basic EPS | CN¥0.28 | CN¥0.22 | (CN¥0.12) | (CN¥0.39) | (CN¥0.81) |
| Diluted EPS | CN¥0.28 | CN¥0.22 | (CN¥0.12) | (CN¥0.39) | (CN¥0.81) |
| Revenue Per Share | CN¥1.44 | CN¥1.49 | CN¥0.87 | CN¥0.51 | CN¥0.26 |
| Shares | |||||
| Basic Shares Outstanding | 415.6M | 363.7M | 363.3M | 358.4M | 358.1M |
| Diluted Shares Outstanding | 415.6M | 363.7M | 363.3M | 358.4M | 358.1M |
| Profitability Metrics | |||||
| EBITDA | 47.2M | 112.6M | (35.6M) | (155.0M) | (321.7M) |
| D&A | 11.5M | 23.5M | 25.1M | 20.0M | 13.9M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026